Prague, Czechia

Iva Vancurova

This inventor holds 1 USPTO granted patent. Top assignee: Spofa, Spojene Podniky Pro Zdravotnickou Vyrobu. Active years: 1987.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 1987

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Iva Vancurova: Innovator in Antineoplastic Research

Introduction

Iva Vancurova is a notable inventor based in Prague, Czech Republic. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with potential therapeutic effects against leukemia. Her work exemplifies the intersection of innovation and healthcare.

Latest Patents

Iva Vancurova holds 1 patent for her invention titled "Basic ethers of 7-oxo-7H-benzo(c) fluorene and a process for their preparation." This patent describes a method for creating basic ethers that have demonstrated pronounced antineoplastic and immunosuppressive effects in mammals suffering from leukemia. The technique involves the aminoalkylation of 5-hydroxy-7-oxo-7H-benzo(c) fluorene and its corresponding nuclear substituted derivatives on the hydroxylic oxygen atom.

Career Highlights

Iva is associated with Spofa, Spojene Podniky Pro Zdravotnickou Vyrobu, a company dedicated to healthcare products. Her innovative work has positioned her as a key figure in the pharmaceutical industry, contributing to advancements in cancer treatment.

Collaborations

Iva has collaborated with notable colleagues, including Karel Rezabek and Slavjanka Cernochova, who have supported her research endeavors. Their teamwork has fostered an environment of innovation and discovery in their field.

Conclusion

Iva Vancurova's contributions to pharmaceutical research highlight her role as an inventor dedicated to improving healthcare outcomes. Her innovative work continues to inspire advancements in the treatment of leukemia and other medical conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…